Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for injection sclerotherapy for esophageal variceal bleeding, effective May 15, 2026. Here's what billing teams need to do.
CMS injection sclerotherapy coverage policy changes don't happen often, but when they do, they hit gastroenterology and interventional endoscopy practices hard. This modification updates the billing guidelines governing when Medicare will pay for sclerotherapy used to control or prevent bleeding from esophageal varices. The policy does not list specific CPT or HCPCS codes in the available documentation — your billing team should verify current applicable codes directly against the CMS policy source and your MAC's local coverage determinations before the May 15, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Injection Sclerotherapy for Esophageal Variceal Bleeding |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Gastroenterology, Interventional Endoscopy, General Surgery, Hepatology |
| Key Action | Audit your documentation and medical necessity criteria for esophageal variceal sclerotherapy claims before May 15, 2026 |
CMS Injection Sclerotherapy Coverage Criteria and Medical Necessity Requirements 2026
The core question with any CMS esophageal variceal sclerotherapy coverage policy is whether the procedure is being performed for an acute, life-threatening bleed or as prophylactic treatment in a patient with known varices. That distinction matters for medical necessity, and it matters for reimbursement.
CMS has historically covered injection sclerotherapy for esophageal variceal bleeding when the procedure is performed to control active hemorrhage or to prevent rebleeding in patients with documented portal hypertension and high-risk varices. The modified policy refines how those criteria apply. Because the full policy detail is not available in the current documentation, billing teams should pull the complete policy text from the CMS source at app.payerpolicy.org before the effective date of May 15, 2026.
Medical necessity documentation is the centerpiece of every clean claim for this procedure. Your endoscopist's report needs to show why sclerotherapy was chosen — active hemorrhage, failed band ligation, anatomical factors, or other clinical justification. "Esophageal varices" alone won't hold up a claim. The record needs to connect the patient's condition to the specific criteria CMS requires.
Prior authorization is not typically required for emergent endoscopic procedures under Medicare. But if your practice performs elective or prophylactic sclerotherapy, check your Medicare Administrative Contractor's local coverage determination. Some MACs have issued LCDs that add prior authorization or prior approval requirements on top of the national policy. Don't assume national policy is the whole picture.
Whether injection sclerotherapy for esophageal variceal bleeding is covered under Medicare depends on the clinical context, the documentation, and — in some regions — what your MAC has layered on top of this national guidance. That's three separate things to verify before May 15, 2026.
CMS Injection Sclerotherapy Exclusions and Non-Covered Indications
CMS has consistently drawn a line between therapeutic sclerotherapy for documented variceal bleeding and procedures performed in circumstances it considers outside covered indications.
Prophylactic sclerotherapy in patients with varices who have never bled is an area of ongoing scrutiny. CMS and many MACs do not consider primary prophylaxis — treating varices before any bleeding episode — to be medically necessary under Medicare's standard coverage policy. This is the area where claim denial risk is highest, and where your documentation needs to be bulletproof.
Sclerotherapy for gastric varices rather than esophageal varices may also fall outside covered indications depending on how the claim is coded and documented. These are anatomically and clinically distinct, and CMS may treat them differently. If your physicians treat both, make sure your coding reflects the correct site and your documentation supports it.
Repeat sessions without clear documentation of clinical response or ongoing medical necessity are another exposure point. CMS expects to see that each session is justified individually — not just that the patient had a bleed six months ago. Train your physicians to document the current clinical rationale for each procedure, every time.
Coverage Indications at a Glance
Because the full policy detail is not available in the current documentation, this table reflects CMS's established coverage framework for injection sclerotherapy for esophageal variceal bleeding. Verify all entries against the updated policy text before May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Active esophageal variceal hemorrhage | Covered | Not specified in available data | Strong medical necessity documentation required |
| Secondary prophylaxis (prevention of rebleeding after a prior bleed) | Covered | Not specified in available data | Clinical history and documentation of prior bleed required |
| Primary prophylaxis (no prior bleeding episode) | Not Covered / Disputed | Not specified in available data | High claim denial risk; check MAC LCD |
| Gastric variceal bleeding | Coverage varies | Not specified in available data | Site-specific coding and documentation required; verify with MAC |
| Repeat sessions without documented ongoing necessity | Not Covered | Not specified in available data | Each session requires individual medical necessity justification |
CMS Injection Sclerotherapy Billing Guidelines and Action Items 2026
The real issue with a modified CMS coverage policy is the gap between when the change is published and when your billing team actually adjusts its workflows. That gap is where denials happen. Close it before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the full policy text now. The policy is available at app.payerpolicy.org. Read it. Don't rely on summaries — including this one — for your compliance decisions. The full criteria, any new documentation requirements, and any changes to covered indications live in the source document. |
| 2 | Check your MAC's LCD. CMS national policy sets the floor, not the ceiling. Your Medicare Administrative Contractor may have issued a local coverage determination that adds requirements for esophageal variceal sclerotherapy billing. Search your MAC's website for any active or pending LCDs related to endoscopic sclerotherapy before May 15, 2026. |
| 3 | Audit your documentation templates. Your endoscopy procedure notes need to capture the clinical indication for sclerotherapy with specificity. Active hemorrhage, variceal grade, prior bleed history, treatment alternatives considered — these elements support medical necessity and protect your claims. If your current templates don't prompt for them, update them now. |
| 4 | Verify your CPT and ICD-10 coding. This policy does not list specific codes in the available documentation. Work with your coding team to confirm which CPT codes you're currently using for injection sclerotherapy and whether those codes align with the updated policy. A mismatch between procedure code and documented indication is a fast path to claim denial. |
| 5 | Brief your gastroenterology and hepatology physicians. CMS policy changes on esophageal variceal procedures affect what your physicians need to document, not just what your billing team needs to submit. Hold a brief before May 15, 2026 — even 20 minutes — to walk through the updated medical necessity criteria and documentation expectations. |
| 6 | Review your prior authorization workflow for elective cases. For non-emergent sclerotherapy, confirm whether your MAC or any commercial crossover plans require prior authorization. Build that check into your scheduling workflow so it happens before the patient arrives, not after the claim is denied. |
| 7 | Flag this for your compliance officer. If your practice does significant volume in esophageal variceal procedures, this policy modification warrants a formal compliance review. Your compliance officer should assess whether your current documentation and coding practices meet the updated criteria — before the first claim goes out under the new policy. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Injection Sclerotherapy for Esophageal Variceal Bleeding
The policy data provided for this modification does not include specific CPT, HCPCS, or ICD-10 codes. Do not assume which codes apply based on general knowledge alone — code applicability under a modified CMS coverage policy needs to be confirmed against the official policy text.
What to Verify with Your Coding Team
Work with your certified coders to confirm the correct procedure codes for endoscopic injection sclerotherapy of esophageal varices. Your coders should cross-reference those codes against the updated CMS policy to confirm coverage status, and against your MAC's LCD for any additional code-level restrictions.
Your ICD-10-CM diagnosis coding should accurately reflect the clinical scenario: acute hemorrhage, history of hemorrhage, the underlying cause of portal hypertension (cirrhosis, portal vein thrombosis, etc.), and any complicating factors. Diagnosis codes drive medical necessity determinations. Weak or mismatched diagnosis coding is one of the most common reasons these claims get denied.
If your practice uses a charge capture tool or EHR-driven charge router, confirm that the code mappings are updated to reflect the current policy criteria before May 15, 2026. Stale mappings from a prior policy version will generate claims that don't meet the new criteria.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.